Emyria Ltd · ASX:EMD
Emyria — Shareholder Meeting (November 2020)
28 slides from Emyria's shareholder meeting presentation, Nov 13, 2020
Slide 1: AGM presentation November 2020
For personal use only AGM presentation November 2020 Michael Winlo - MD & CEO ASX:EMD DRAFT
Slide 2: Emyria name origin
Emyria (em-meer-reeuh) Derived from ‘Myriad’: Noun: an indefinitely great number of persons or things. Adjective: of an indefinitely great number; innumerable.
Slide 3: Disclaimer and notices
Disclaimer and notices This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any ju
Slide 4: Funding history & milestones in first 9 months
Funding Funding history history & milestones & milestones in6first in first 9 months months For personal use only History Milestones • Listed on the ASX, 12 February 2020 (ticker: EMD) • $1m+ total contract value of data deals • Last reported cash position (Q3, 2020): $4.2m • Unique insights a sourc
Slide 5: Experienced board with drug development and tech focus
Experienced board with drug development and tech focus For personal use only Key Person Role Previous Experience Dr Stewart Washer Chairman & Founder Cynata (ASX:CYP) – stem cells Orthocell (ASX:OCC) – regenerative medicine Botanix (ASX:BOT) – CBD (synthetic) for topical and antimicrobial use AusCan
Slide 6: Traditional drug development
Traditional drug development Product registration Product monitoring For personal use only Initial drug Potential registration indication expansion Discovery Preclinical Preclinical Studies studies Phase 1, 2, 3 clinical trials Post registration monitoring what is the drug? is it safe? is it still s
Slide 7: Real world evidence (RWE) accelerates drug registration
Real world evidence (RWE) accelerates drug registration Product registration Product monitoring For personal use only Initial drug Potential registration indication expansion Discovery Preclinical Preclinical Studies studies Trials + real-world data Post registration monitoring what is the drug? is
Slide 8: RWE saves time and costs in drug registration
RWE saves time and costs in drug registration Product registration Product monitoring For personal use only Initial drug Potential registration indication expansion Discovery Preclinical Preclinical Studies studies Trials + real-world data Post registration monitoring what is the drug? is it safe? i
Slide 9: Why registration matters
Why registration matters For personal use only Special Access Scheme (eg. all cannabinoid medicines in Aus) Submit notification Consent to Collect prescription application Check State / treatment with Consultation with Territory Is stock available? doctor + requirements unregistered Patient pays out
Slide 10: How Emyria accelerates drug registration
How Emyria accelerates drug registration For personal use only Emyria Care Emyria Data Drug registration Emyria data helps answer: Regulator-grade data: • What dose is most effective? • Validated clinical endpoints • Which patient sub-groups • Patient-reported outcomes Novel benefit most? • Precise d
Slide 11: Emyria successes to date
Emyria successes to date For personal use only Emyria Care Emyria Data Drug registration • Over 3,000 referrals • Over 2.5M data points • Multiple global clients • Over 54 medical needs • Over $1M data deals • Multiple unmet needs • Australia + UK • Unique IP captured • Growing therapy base Emyria’s
Slide 12: Emyria Care, Emyria Data, Drug registration
For personal use only Creates Accelerates Emyria Care Emyria Data Drug registration Emyria care Emyria data Informs informs
Slide 13: Emyria elevates care for patients with unmet medical needs
For personal use only Emyria elevates care for patients with unmet medical needs DRAFT
Slide 14: We support unmet needs with high cost burden
Emyria Care We support unmet needs with high cost burden For personal use only Core unmet need Size of patient Australian health system Notes References (% of Emyria patients) population in Australia costs 44.6% of patients living with Chronic pain 3.37 million $12.64 billion chronic pain also exper
Slide 15: We train and develop clinical experts
Emyria Care We train and develop clinical experts For personal use only Dr Jennifer Dr Alistair Dr Phil Finch Morgan Vickery Dr Nelson Lau Dr Jennifer Tai Dr David Gunn Dr Ben Addison Pictured: Some of Emyria’s clinical team. For more details on our care team, please visit www.emyria.com
Slide 16: We specialise in novel & unregistered treatments
Emyria Care We specialise in novel & unregistered treatments For personal use only Revenues Treatment Clinical pipeline Product QA service Patient Data selection checks design care deals Cannabinoids AUS (Emerald Clinics) UK (Sapphire Clinics) Psychedelics * Active Others In planning * Under Austral
Slide 17: Case Study - Bob
Case Study - Bob For personal use only • Vietnam Veteran | injured by fall in 1969 | multiple fractures • Chronic back pain | peripheral neuropathy from Agent Orange | PTSD • At initial visit: oxycontin | buprenorphine | pregabalin | gabapentin | PEA duloxetine – with little relief and side effects.
Slide 18: Emyria Care growth story so far
Emyria Care Growth story so far For personal use only Enter UK partnership with Sapphire Medical - first accredited medicinal cannabis clinic in the UK. Opened a specialist clinic for mental health and substance Further growth in abuse in Northern NSW clinical services and Clinic locations across Au
Slide 19: Emyria Data
For personal use only Emyria Data indication-specific dose response insights Insights + services to strategic trial design help developers obtain a drug registration (i.e. a clinical trial execution “label claim”) registration and repurposing submission support
Slide 20: Revenues from data & registration milestones
Emyria Data Revenues from data & registration milestones Data insights For personal use only revenue Collect Patient Product- Clinical Unmet medical needs data stratification specific insights trials Registration Monitoring Insomnia Chronic non-cancer pain Autism Mental Health (PTSD, depression) Che
Slide 21: Case Study - Spectrum
Case Study - Spectrum For personal use only • Emyria approached in 2019 to develop a pharmacovigilance product registry for largest cannabis company in the world • To include safety data for Australian patients taking Spectrum products seen Total contract values through Emerald Clinics. over $1M (AU
Slide 22: Case Study - Zelira
Case Study - Zelira For personal use only • Emyria approached in 2019 and provided insomnia-related outcome insights from Emyria’s real-world data. These insights supported a Phase 2 trial. • In parallel, Emyria conducted a home-based Phase 1 clinical trial via our national network - Emerald Clinics
Slide 23: Emyria Data growth story so far
Emyria Data Care Growth story so far For personal use only More data deals, unique IP to Phase 1 trial Product registry support new (Opioids) Product registry (UK) product (AUS) Trial Trial development (Insomnia) (Autism) Feb Care Mar Apr Care May Jun Care Jul Aug Care Sep Oct Care Nov Next
Slide 24: Emyria's digital health patient-centric care
For personal use only Emyria’s digital health patient-centric care in the home improve clinical efficiency and evidence capture Emyria is investing in the future of care helps clinical team stay connected to patients supports delivery of data- driven care plans
Slide 25: Case Study - Openly
Case Study - Openly For personal use only Health screening, powered by your smartphone and backed by a clinical team • Mobile app captures clinical vital signs using just a Smartphone - eg heart rate & heart rate variability - important signs of physiological stress (eg early signs of infection or m
Slide 26: Emyria's digital health platform
Emyria’s digital Simple, Scalable Screening in Seconds Actionable Insights health platform Mobile-based supports large populations Easy to use screenings and objective clinical measurements Aggregates population health data to manage risks For personal use only Emyria’s digital health technology imp
Slide 27: Emyria positioned to rapidly bring new treatments to patients
Emyria positioned to rapidly bring new treatments to patients For personal use only Emyria Care Emyria Data Drug registration • Continued growth of • Partnership growth patient base • Unique IP to support • New therapeutic areas new products • Focus on high unmet • Additional service • Additional pa
Slide 28: Contact Information
For personal use only Contact Information Michael Winlo: mwinlo@emyria.com Investors: investors@emyria.com Media: media@emyria.com General: info@emyria.com ASX:EMD DRAFT